MMJ holds a CAD$2.5 million convertible note in Dosecann ("Convertible Note"). This investment was made by MMJ as part of a CAD$7.5 million capital raising by Dosecann in January 2018 at a pre-money valuation of CAD$11.5 million, valuing Dosecann at the time at CAD$19 million. The Convertible Note gives MMJ the ability to acquire 2.5 million Dosecann common shares (that is, at CAD$1.00 per common share, before accounting for accrued interest).
MMJ also holds warrants in Dosecann that give MMJ the ability to acquire a further 1.25 million Dosecann common shares at CAD$1.20 per common share. MMJ is considering whether to exercise these in-the-money warrants or exchange them for similar instruments in Cannabis Wheaton.
As part of the Acquisition, MMJ's convertible note, plus accrued interest, will either be converted into Dosecann common shares and exchanged for Consideration Shares on the closing of the Acquisition or will otherwise be exchanged for convertible securities of Cannabis Wheaton based on the exchange ratio used in the Acquisition.
The Acquisition is subject to a number of conditions and is expected to close on or about 30 April 2018.
Jason Conroy, CEO of MMJ, said "We are delighted to have more than doubled our money on the investment in Dosecann in such a short space of time. It also shows that Canada remains a jurisdiction where corporate activity in the cannabis space can deliver significant returns on investment for MMJ's shareholders."
To view the release, please visit:
About MMJ PhytoTech Ltd
In October 2017, MMJ PhytoTech Limited (ASX:MMJ) announced its strategy to become an incubator for strategic investments across regulated jurisdictions globally covering the entire cannabis value chain.
Following the successful listing of United Greeneries Holdings Ltd ("United Greeneries") and Satipharm AG ("Satipharm") on the TSX-V through Harvest One Cannabis Inc. (CVE:HVT), MMJ has focused on the identification of a number of independent strategic investment opportunities that have the potential to deliver significant value to the Company's shareholders.
MMJ is actively pursuing early stage opportunities with the ability to deliver significant future revenue and the opportunity to provide dramatic global synergistic value as regulatory frameworks in key international markets continue to evolve. MMJ is targeting the full range of emerging cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D, hemp food products and retail.
MMJ currently holds an equity stake of 53,333,333 shares in Harvest One, 100% ownership of Israeli-based R&D division PhytoTech Therapeutics Limited ("PTL") and strategic holdings in e-Sense Lab Limited (ASX:ESE) and private Canadian-based company WeedMe Inc.
ContactInvestor and Media Enquiries:
Chief Executive Officer